The forward-looking information contained herein, including, without limitation, statements related to Mikra reaching additional customers in 2024, are made as of the date of this news release and are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, the effectiveness and benefits of CELLF 2.0 are as anticipated, customer interest in Mikras products including CELLF 2.0 and resulting sales will be as anticipated, its expectation that the nutraceutical market will develop as currently anticipated, the nutraceutical market will continue to be a multi-billion dollar high-margin market, the introduction of new products and brands will generate additional revenue, expectations that CELLF, CELLF 2.0, RESCUE, SERENITY, PROTECT and other new nutraceutical products to be developed by Mikra will gain market acceptance along with the expansion of the market for nutraceutical products, as well as other considerations that are believed to be appropriate in the circumstances

After the completion of the study, it was noted that there appeared to be a significant reduction in the body weight of these murine models, including a reduction of excess body lipids
Can J Vet Res 70:2027 Kimura K, Goff JP, Kehrli ME (1999) Effects of the presence of the mammary gland on expression of Neutrophil adhesion molecules and Myeloperoxidase activity in Periparturient dairy cows
If symptoms arise later, its more likely due to other factors such as dietary changes or stress
Is Semaglutide Levocarnitine Approved By the FDA